Opioid receptors interact with a variety of ligands, including endogenous peptides, opiates, and thousands of synthetic compounds with different structural scaffolds. In the absence of experimental structures of opioid receptors, theoretical modeling remains an important tool for structurefunction analysis. The combination of experimental studies and modeling approaches allows development of realistic models of ligand-receptor complexes helpful for elucidation of the molecular determinants of ligand affi nity and selectivity and for understanding mechanisms of functional agonism or antagonism. In this review we provide a brief critical assessment of the status of such theoretical modeling and describe some common problems and their possible solutions. Currently, there are no reliable theoretical methods to generate the models in a completely automatic fashion. Models of higher accuracy can be produced if homology modeling, based on the rhodopsin X-ray template, is supplemented by experimental structural constraints appropriate for the active or inactive receptor conformations, together with receptor-specifi c and ligand-specifi c interactions. The experimental constraints can be derived from mutagenesis and cross-linking studies, correlative replacements of ligand and receptor groups, and incorporation of metal binding sites between residues of receptors or receptors and ligands. This review focuses on the analysis of similarity and differences of the refi ned homology models of m , d , and k -opioid receptors in active and inactive states, emphasizing the molecular details of interaction of the receptors with some representative peptide and nonpeptide ligands, underlying the multiple modes of binding of small opiates, and the differences in binding modes of agonists and antagonists, and of peptides and alkaloids.
INTRODUCTION
Clinical interest in opioid receptors (ORs) is related to the development of strong analgesics without potential for abuse or adverse side effects. This task, however, cannot be accomplished without understanding the differences in the OR subtypes as well as the modes of interactions of drugs/ ligands with these receptors.
Research on ORs was signifi cantly advanced by the cloning of d -opioid (DOR), m -opioid (MOR), and k -opioid (KOR) receptors in the early 1990s. 1 , 2 Sequence comparison confi rmed that ORs belong to the rhodopsin-like family of G-protein-coupled receptors (GPCRs). 1 ORs are composed of a core domain of 7 transmembrane (TM) a -helices and an adjacent, peripheral helix 8 (IL4), are connected by 3 extracellular (EL1, EL2, EL3) and 3 intracellular (IL1, IL2, IL3) loops, and contain glycosylated N-terminal and palmitoylated C-terminal domains of different sizes. ORs demonstrate high sequence identity in their TM domain (73%-76%) and in ILs (63%-66%) and large divergence in N-and C-terminal domains and ELs (34%-40% identity). ORs are activated by either endogenous peptides or exogenous opiates. The endogenous opioid peptides such as b -endorphin, Leu-and Met-enkephalins, dynorphins, and many others are mainly derived from 3 precursors, proopiomelanocortin, proenkephalin, and prodynorphin. They are found mostly in central and peripheral neurons, and also in gut, lungs, spleen, heart, and blood cells. 3 , 4 In addition, several opioid peptides have been isolated from cow ' s milk and frog skin. The majority of opioid peptides contain the core tetrapeptide, Tyr-Gly-Gly-Phe, important for high affi nity and bioactivity. 5 In frog-skin-derived peptides the " Gly-Gly " motif is substituted by D-stereoisomers of Ala, Met, or Ile. Pharmacological studies indicate that no family of endogenous peptides is exclusively associated with a particular receptor type. 6 The need for highly selective and potent agonists and antagonists stimulated the design of numerous synthetic opioid peptides. Thousands of linear peptides have been synthesized, some of them demonstrating subtype selectivity. To improve ligand selectivity, conformational and topographical constraints have been incorporated into the peptide ligands, and several highly selective cyclic peptides have been generated. 5 The fi rst highly d -selective enkephalin E435 analog, the cyclic peptapeptide Tyr-c[DPen-Gly-Phe-D-Pen]OH (DPDPE), was designed using cyclic bridging via a disulfi de and the topographically constrained D-amino acid D-Pen (Pen, penicillamine, b ' b -dimethylcysteine). 7 m -Selective cyclic dodecapeptide antagonists lacking the characteristic " Tyr-Gly-Gly-Phe " motif were developed based on the somatostatin sequence. 8 , 9 Active cyclic analogs of dynorphin A (1 -11) and (1 -13) were also produced by incorporating disulfi de cross-link between cysteines in positions 5 -11, 5 -10, 5 -9, 4 -9, 6 -10, 8 -12, 8 -13, 5 -13, 10 between L, D-Cys and L, D-Pen in positions 5 -11, 11 or by introduction of a lactam bridge between residues in positions 2 -5, 12 2 -6, 3 -7, or 5 -8. 13 Most of these cyclic dynorphin analogs demonstrated high k -and m -affi nity, and some, such as c-[D-Asp3, Lys7]DynA(1 -11)NH 2 were moderately k -selective. 13 The properties of these cyclic opioid peptides have been reviewed in detail by Hruby and Agnes. 5 Synthetic nonpeptide opioid ligands belong to several structural classes, such as morphine analogs, bimorphinans, benzomorphans, phenylpiperidines, phenylpiperazines, 4-anilinopiperidine, methadone analogs, and arylacetamides. 14 The correspondence of key structural elements between opioid peptides and nonpeptides is not always obvious.
Except for the recently crystallized rhodopsin, 15 , 16 structural data on individual GPCRs, including ORs, are limited; therefore theoretical modeling remains an important tool for structure-function analysis of these receptors. 17 Modeling of ligand-receptor complexes is usually performed to achieve several goals: to explain the experimental results of ligand-receptor interactions; to understand the molecular mechanism of ligand selectivity and ligand agonist or antagonist properties; or to propose a receptor-based pharmacophore model for agonists and antagonists that can provide a basis for virtual screening of future drug leads and for structure-based drug design.
Depending on the research goal, the modeling algorithm can include any of the following steps, which will be described in further detail: (1) identifi cation of the bioactive conformation of the opioid ligands based on their structure activity relation (SAR) and theoretical and experimental conformational studies; (2) experimental studies of receptor-ligand interactions to uncover key ligand-receptor contacts; (3) homology modeling of the receptor using the rhodopsin template and additional experimental constraints appropriate for a specifi c receptor in its active or inactive states; (4) ligand docking using experimentally determined key interactions across a set of structurally similar and dissimilar ligands to develop, independently, pharmacophore models for agonist and antagonists.
Bioactive Conformation of Opioid Ligands
Small alkaloids, such as morphine analogs (eg, morphine, naltrindole (NTI), oxymorphinole (OMI), spiroindanyloxymorphone (SIOM), naloxone, naltrexone, etorphine) and benzomorphans (bremazocine), as well as the larger bimorphinans (norBNI) and phenylpiperazines (BW373U86) ( Figure 1 ), have relatively rigid structures that must represent their bioactive conformations. [18] [19] [20] [21] Some rotational fl exibility is allowed around a few rotatable bonds such as in the N-allyl or N-cyclopropylmethyl groups of morphinans, in C-7 substituents of oripavines, at fumatate moiety of b -FNA, and the diethylamide group of BW373U86. The possible uncertainties resulting from such limited fl exibility can be analyzed during ligand docking.
Selective agonists based on the arylacetamide scaffold are more conformationally fl exible. Rotation around 3 single bonds (ie, c 1, c 2, and c 3 angles, see Figure 1 ) dramatically changes the relative orientation of the key pharmacophore elements of U69,593: the ammonium moiety of its pyrrolidine ring, the amide carbonyl group, and the phenyl group. The bioactive conformation of arylacetamides can be deduced from the superpositions of different analogs with structural restrictions introduced at the corresponding dihedral angles. 22 The reported X-ray structure of U69,593 23 overlaps well with all low-energy conformations of structurally restricted arylacetamides and therefore can be proposed as the bioactive conformation.
In the crystal structure of the m -selective agonist cis(+)-3-methylfentanyl, 18 the central piperidine ring is in a chair conformation with 4-phenylpropanamide and N-phenethyl (in its extended conformation) in equatorial positions. Molecular dynamics simulations indicate high populations of different orientations of fentanyl analogs owing to torsional fl exibility at 3 angles that defi ne orientation of N-phenethyl ( c 1 and c 2) and of N-phenylpropanamide ( c 3). 24 Docking of fentanyl analogs into a MOR model can be used to unequivocally identify the receptor-bound conformation of the ligand.
Linear opioid peptides are very fl exible and can adopt a variety of different conformations in solution. To determine the bioactive conformations of opioid peptides, a great number of cyclic peptides have been synthesized. 5 Small cyclic peptides are particularly useful, as they adopt a restricted number of conformations that can be theoretically predicted or experimentally determined. Moreover, introduction of conformational constraints into small cyclic ligands allows exploration of the structural requirements for opioid peptides to effectively and selectively interact with ORs. During the past few years we have developed a large number of cyclic tetrapeptides with high affi nity toward MOR, DOR, and KOR. [25] [26] [27] [28] [29] [30] [31] [32] [33] In particular, the cyclic tetrapeptides JOM13 (Tyr-c[D-CysPhe-D-Pen]OH, cyclized through a disulfi de bond) and JOM6 (Tyr-c[D-Cys-Phe-D-Pen]NH2, cyclized via an ethylene dithioether), are highly potent and selective for DOR and MOR, respectively. 25 The design of k -selective tetrapeptides based upon the same type scaffold as JOM13 and JOM6 has E436 been more challenging. Although cyclic tetrapeptides with high k -selectivity have not been obtained, the cyclic tetrapeptide, MP16 (Tyr-c[D-Cys-Phe-D-Cys]NH2, cyclized via a disulfi de) demonstrates nanomolar affi nity to KOR. 26 Subsequent modifi cations of the parent tetrapeptides were directed toward elucidation of structural requirements for Tyr1 and Phe3 residues, which are key residues for recognition of cyclic tetrapeptides by ORs. [25] [26] [27] [28] [29] [30] [31] [32] [33] The following 
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conclusions were derived from these studies ( Table 1 ) . First, the importance of aromatic residues in positions 1 and 3 was confi rmed for all selective peptides. Second, cyclization via an ethylene dithioether bridge favors MOR binding, while the smaller disulfi de-containing cycle is preferred for peptide recognition by DOR and KOR. Third, restriction of the Phe3 side chain in the trans ( c 1~180°) rotamer is favorable for MOR and KOR high binding affi nity, while restriction of the Phe3 side chain in the gauche + ( c 1~-60°) conformation provides improved DOR affi nity. Fourth, the presence of a C-terminal amide is important for ligand binding to MOR and KOR, while a free C-terminal carboxylate enhances DOR affi nity. Fifth, the presence of D-Cys4 in place of D-Pen4 in the tripeptide cycle dramatically increases binding affi nity to KOR, while retaining high affi nity to MOR and DOR. A combination of SAR, X-ray, and nuclear magnetic resonance (NMR) studies, and computational analysis of the cyclic tetrapeptides allowed us to deduce the bioactive conformations of JOM13, 25 , 31 JOM6, 32 , 34 and MP16, 26 which appeared to be complimentary to the binding pockets of modeled ORs. 26 , 34 , 35 
Experimental Studies of Receptor-Ligand Interactions
Experimental studies useful for developing a crude topographical ligand-receptor interaction model include comparative affi nity determination of ligands in receptor mutants, correlated replacements of ligand and receptor functional groups, covalent cross-linking of ligand to receptors, and the design of metal binding sites between ligand and receptors. Particularly important is the identifi cation of specifi c interactions conferring ligand selectivity and agonist or antagonist properties.
Studies of OR chimeras and site-directed mutants revealed that the ligand binding pocket is located between TMs 2 -7 and is covered by EL1, EL2, and EL3. Published mutagenesis data on ORs delineated a set of more than 20 residues in the TM a -bundle important for binding of opioid ligands. [36] [37] [38] It is assumed that conserved residues from TM 3 -7 of ORs represent the common opioid pocket for the tyramine " message " part of opioid peptides and alkaloids, which triggers receptor transition to the active or inactive conformation, while subtype-specifi c residues from TMs 5 -7, EL1, EL2, and EL3 contact the " address " part of the ligands, providing recognition of selective ligands by the corresponding receptors. 39 , 40 The residues from the binding pocket, essential for ligand binding, are mostly conserved across the ORs and include Asp(3.32), Tyr(3.33), Lys(5.39), Phe(5.47), Trp(6.48), Ile(6.51), His(6.52), Ile(6.53), Ile(7.39), and Tyr(7.43). [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] Binding determinants for small alkaloids (morphine, codeine) reside in TMs 5 -7. 51 Variable binding pocket residues confer selectivity. For example, Lys108 in EL1 of DOR prevents binding of the m -selective DAMGO 52 ; residues from EL2 and EL3 confer the selectivity of dynorphin to KOR 39 , 53-55 ; and variable residues from EL3 and adjacent helices, particularly Lys303(6.58), Trp318(7.35), and His319(7.73) of MOR and the corresponding Trp284(6.58) and Leu300(7.35) and His301(7.36) of DOR are important for selective binding of morphine, DAMGO, and fentanyl analogs to MOR, [56] [57] [58] and of DPDPE, SNC80, and TAN67 to DOR. 37 , 59 , 60 Glu297(6.58) in KOR is involved in binding of norBNI. 61 Several conserved residues in the binding pocket, such as Asp(3.32), Tyr(3.33), Lys(5.39), His(6.52), Trp(6.48), and Tyr(7.43), as well as divergent residues in positions 6.58 and 7.35, also participate in receptor activation. 42 , 44 , 47 , 56 , 62-65 Of interest, in the mutants D128K(3.32) of DOR and H297Q(6.52) of MOR, the antagonist naloxone demonstrates agonistic properties. 47 , 62 In addition, the H287Q(6.52) mutant of MOR is more resistant to b -FNA irreversible binding, 66 which acts at this mutant as a partial agonist. 66 In many cases it is diffi cult to unequivocally distinguish between residues from the binding site, an allosteric regulation site, or those involved in receptor structural changes without detailed analysis of ligand-receptor interactions. To date, direct contacts between opioid ligands and corresponding receptor residues have been documented in only a few cases. Among these are interactions between the basic N + of the opioid ligand and Asp147(3.32) in MOR, 50 between the fumarate moiety of the irreversible m -antagonist b -FNA and Lys233(5.39) in MOR, 67 and between the N-17 ' basic nitrogen of norBNI and the acidic Glu297(6.58) of KOR 61 or the Recent mutagenesis studies have allowed us to develop a topographical scheme of key ligand-receptor contacts between JOM6 and MOR, 34 which is presented in Figure 2 . These studies provided evidence for the formation of a metal binding site by Asp216(EL2) and His319 (7.36) 
Homology Modeling of Opioid Receptors
During the mid to late 1990s several models of opioid receptors were proposed based on the nonhomologous bacteriorhodopsin or low resolution electron microscopy maps of rhodopsin. 22 , 24 , 57 , 71-77 We developed at that time a computational approach for modeling the transmembrane, 7 a -helical bundle of GPCRs that employed an iterative distance geometry refi nement with an evolving system of interhelical hydrogen bonding constraints 78 and applied it to the modeling of MOR, DOR, and KOR 40 and other GPCRs. 79 The rhodopsin model calculated with this approach was close to the subsequently published crystal structure (root mean square deviation [rmsd] 2.88 Å for 186 C a -atoms in the TM domain). Other methods for GPCR modeling that do not rely on a structural template include MembStruck 80 and PREDICT, 81 which also produced realistic models of rhodopsin (rmsd of 3.1 Å and 3.87 Å, respectively, vs the rhodopsin X-ray structure in the 7TM domain) and were used to model other GPCRs. Although such ab initio methods were able to achieve medium accuracy in the modeling of the a -helical TM domains of GPCRs, they failed to correctly predict the structure of the receptor loops. 80 This could seriously affect the analysis of ligand-receptor interactions, especially for peptide ligands since ELs are known to participate in contacts conferring ligand selectivity. 82 , 83 Nevertheless, these various methods yielded results that were consistent with available ligand SAR and confi rmed the ligand-based pharmacophore models. 14 , 35 It has been widely demonstrated that the most reliable computer-based technique for generating 3-dimensional models is via homology modeling. 84 The publication of the rhodopsin crystal structure 16 , 85 has made homology modeling of receptors from the rhodopsin-like family possible, [86] [87] [88] [89] and several opioid receptor models based on the rhodopsin template have subsequently been produced. 37 , 65 , 88 , 90 , 91 Knowing the structural template, the homology models can be generated using MODELER, 92 , 93 or publicly available Web servers, such as SWISS-MODEL, EsyPred3D, Robetta, CPHmodels, or SDSC1, 94-98 or downloaded from databases, such as ModBase. 99 The accuracy of comparative modeling is highly dependent on the sequence identity between the target sequence of interest and the template sequence. High accuracy comparative modeling (rmsd ~1Å) can be achieved when the target and template proteins have sequence identity of more than 50%, while the accuracy drops when the identity of target and template sequences is less than 30%. 84 The opioid receptor sequences have only ~20% identity to rhodopsin for all residues and ~29% identity in TM segments. Therefore, automated homology modeling of ORs is likely to result in numerous errors. The major source of errors is from sequence misalignment, 81 , 100 , 101 which can be expected in areas of low sequence identity and in regions of helical distortions. Helical irregularities are indeed observed in the crystal structure of rhodopsin, which exhibits a fragment of 3 10 helix in TM7 and a -aneurisms (one residue insertion) in TM2 and TM5, as well as proline-induced kinks in TMs 1, 2, 4, 5, 6, and 7. 102 These distortions in a -helices may not be present in other GPCRs. Other sources of errors are the divergent loops, which in many cases should be constructed ab initio. 103 Further, the a -helices of modeled proteins may have altered lengths, positions, and orientations relative to E439 the template structure. Indeed, a sequence homology of ~20% between proteins suggests ~1.6 to 2.3 Å rmsd within the helical core, caused by helical shifts. 104 Another problem is related to conformational rearrangement of the receptor during activation. The crystal structure of rhodopsin represents the inactive conformation in complex with the covalently bound inverse agonist, 11-cisretinal. This structure can be used for homology modeling of the antagonist-bound inactive receptor state; however, the active states of rhodopsin and other GPCRs have been shown to differ from the inactive conformations. 15 , 105 The accumulated data from mutagenesis, cross-linking, electron paramagnetic resonance spectroscopy (EPR), and fl uorescence studies suggest that different rhodopsin-like GPCRs share a common active conformation 106 in which TM6 undergoes a signifi cant rigid-body motion in a counterclockwise direction, as viewed from the extracellular side. [107] [108] [109] This results in a signifi cant shift of the intracellular end of TM6 outward from TM3 109 , 110 and TM7, 111 , 112 and toward TM5, 113 opening a cleft on the cytoplasmic surface of the a -bundle for binding of G-proteins. 105 , 114 A relatively smaller motion of TM3 and some conformational changes in the extracellular ends of TMs 1, 2, and 7 have also been observed. 109 , 115-120 Random mutagenesis of DOR provided evidence that the conformational transition originates at the ligand binding pocket near the extracellular ends of TM5, TM6, and EL3 and propagates through TMs 3, 6, and 7 down to a cytoplasmic switch between TMs 6 and 7. 65 Moreover, experimental studies of different GPCRs (eg, rhodopsin, b -adrenoreceptors, DOR) indicate that a conformational transition of the receptor may involve multiple intermediate states. 107 , 109 , 113 , 121-126 Therefore, agonists of different structural types may generate different activated states of receptors, which could be recognized by specifi c proteins involved in distinct transduction and regulation pathways.
Unfortunately, the existing methods for energy optimization, including molecular dynamics or distance geometry refi nement, are unable to correct alignment errors or to reproduce helical shifts and distortions 127 and have been unsuccessful in modeling long irregular loops (>12 residues). 103 Some recent attempts demonstrated moderate improvement of homology models by combining several templates, 128 and some success in modeling helical shifts has resulted from using a new multiscale energy optimization algorithm. 129 Currently, model refi nement requires human intervention and incorporation of additional information. For example, questionable target-template alignments in the area of helical distortions and in the loops of MOR have been clarifi ed by mutagenesis data and construction of helix-loop metal binding sites. 34 In another example, initial homology models of tachykinin NK1 receptors were optimized in the area of the binding site by incorporation of distance constraints from the ligands in their bioactive conformation, using a new algorithm, MOBILE. 89 , 130 Accuracy of models of different functional states can also be improved by iterative distance geometry refi nement with experimental interhelical restraints appropriate for only the active or inactive conformation derived from mutagenesis, crosslinking studies and design of metal binding sites together with ligand-receptor distance restraints. 70 , 88 For example, the important interhelical distance constraints for the positioning of TM6 in the activated receptor state can be deduced from recent data on the formation of disulfi des between TM5 and TM6 in the m 3 muscarinic receptor upon agonist binding 131 and from the existence of an intrinsic allosteric Zn 2+ binding site at the interface of TM5 and TM6 of the b 2 -adrenergic receptor that facilitates agonist binding. 132 Additional constraints for adjusting helix packing in the activated state can be taken from the engineering of an activating metal-coordination center between TM3 and TM7 in b 2 -adrenergic 133 and tachykinin receptors, 134 and also between TM2 and TM3 of the MC4 melanocortin receptor. 135 
Ligand Docking
Ligand docking should satisfy the surface complementarities between ligand and receptor and the key interactions deduced from mutagenesis studies of ligand-receptor interactions. In earlier modeling of receptor-ligand complexes, ligand docking was primarily done manually. In a recent review, Eguchi compared previously published models of receptor-ligand complexes for selective opioid agonists and antagonists that satisfi ed some experimental observations about receptor-ligand interactions and SAR of the ligands. 14 The comparison revealed that although the modeling was based on a common set of experimental data, the proposed models often contradicted each other in the manner of docking similar ligands, such as morphine and its analogs or k -selective arylacetamides. It was unclear, however, whether such contradictions refl ected the existence of multiple modes of ligand binding or appeared as a result of low accuracy of receptor modeling or inaccurate docking methods.
Other important questions, such as differences between binding modes of peptides and alkaloids, and of agonists and antagonists were beyond the scope of the review by Eguchi. To answer these questions pharmacophore models should be developed separately for agonists and antagonists and docked to 3-D structures of the active and the inactive receptor conformations, respectively. Moreover, the models and docking algorithm should be relatively accurate.
Manual docking was recently used for homology-and knowledge-based models of inactive and activated GPCRs to fi nd the position of ligands in the binding pockets that would agree with known ligand-receptor interactions. 88 The resulting models of antagonist-bound dopamine D 1 , muscarinic m 1 , and vasopressin V 1a and agonist-bound DOR, dopamine D 3 , and b 2 -adrenergic receptors appeared to be suitable for the virtual screening of drug leads from databases of drug-like compounds with hit rates from 2% to 37%, depending on docking algorithm and scoring function used. 88 Numerous programs, based on different methods, have been developed to automatically dock small ligands into proteins. These programs include DOCK, 136 GOLD, 137 FlexX, 138 FDS, 139 Glide, 140 LigandFit, 141 ICM, 142 and others. To improve results, the best docking algorithms are combined with different scoring functions. 143 Program performance is largely dependent on the accuracy of the receptor structure (especially in the case of modeled structures), on the fl exibility of the ligand (number of rotatable bonds), and on the nature of the binding site. [143] [144] [145] Receptor fl exibility presents the major complication for automated docking. Almost all currently used programs perform semifl exible ligand docking, where the ligand is considered as fl exible and the protein, as rigid. Such an approach is known to cause errors in computational studies. A few algorithms perform fl exible docking in which limited protein fl exibility, such as side chain motions in the active site, is incorporated. Some recent algorithms use an ensemble of protein structures, pregenerated by molecular dynamic simulations, to account for backbone or side chain fl exibility in structure-based drug design, 146 but they are very computationally intensive. In a recent approach incorporated in MOBILE, 130 an ensemble of homology models was generated much faster using MODELER, 92 and the ligands were docked into an averaged binding site representation using AutoDock. To improve the results obtained, the docking solution that better reproduced the experimentally determined key ligand-receptor interactions was selected and was further utilized for the iterative refi nement of the ligandbound homology models. The refi ned antagonist-bound homology model of tachykinin neurokinin 1 (NK1) receptor obtained in this manner was successfully employed for the virtual search of NK1 antagonists from a database of lead-like compounds. 89 , 147 We have applied a similar method, employing structural constraints to produce a more reliable homology model of the agonist-bound receptor state of MOR in complex with the m -selective cyclic peptide agonist, JOM6. 70 This approach complied with the SAR and key ligand-receptor interactions of relatively fl exible peptide ligands, which is a more complicated task than the docking of more conformationally rigid alkaloids. To reproduce the agonist-bound state, the receptor was calculated together with the bioactive conformation of the cyclic tetrapeptide using experimental distance constraints between ligand and receptor functional groups (see Figure 3 ) . The active receptor conformation was calculated simultaneously using the interhelical distance constraints from the rhodopsin crystal structure to defi ne the positions of TMs 1 to 5 and 7, receptor-specifi c H-bonds, and a set of experimental distance constraints between TMs 3 to 6 and TMs 5 to 6 to defi ne the position of the largely fl exible TM6. The latter constraints were derived from EPR, cross-linking studies, and from engineered metal binding sites. 108 , 131 , 132 The agonist bound conformations of DOR with JOM13 and of KOR with MP16 have also been calculated based on the MOR-JOM6 complex. 25 , 26 The receptor-bound conformations of JOM13 appeared to be very similar to one of the crystal forms of JOM13, 31 while the receptor-bound conformation of MP16 requires a 
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tripeptide cycle conformation that is ~2 kcal/mol higher in energy than the lowest energy state. 26 The differences in binding cavity geometry among MOR, DOR, and KOR are related to the divergence in size, polarity, and charge of residues from the top of TMs 5 to 6, EL2, and EL3. The greatest difference is observed for KOR, whose 3-residue longer EL2 occupies more space between TM3 and TM7 and between TM3 and TM5. The binding pocket in KOR is consequently smaller in the regions between EL2 and TM7 and between EL2 and TM5. KOR also has several negatively charged side chains from EL2 (Asp204, Glu209, Asp216) and EL3 (Glu297) lining the binding cavity, which may have favorable ionic interactions with positively charged groups of k -selective ligands.
In all 3 receptors, the positions of Tyr1 and of the central backbone cycle of tetrapeptide ligands are quite similar, but the orientations and interactions of the ligand Phe3 side chain are different ( Figure 3 ). The common Tyr1 of the tetrapeptides interacts with conserved charged, aromatic, and aliphatic side chains from the binding pockets; the positively charged amine group forms H-bond and ionic interactions with Asp(3.32) and participates in amine-aromatic interactions with Tyr(3.33); and the Tyr1 phenolic hydroxyl can either be an H-acceptor from His(6.52) or an H-donor to -C=O of Ala(5.46), which is excluded from the usual system of intrahelical H-bonds because of the presence of an a -aneurism in TM5. The Phe3 of JOM13 adopts a gauche+ orientation that can be easily accommodated in the relatively hydrophobic environment of DOR between TM3, EL2, and TM7. In contrast, in MOR and KOR the corresponding area is partially fi lled by polar side chains from EL2. Therefore, the properties of the binding site in MOR and KOR favor the trans rotamer of Phe3, which is shifted closer to the extracellular surface. This is in agreement with the independently deduced pharmacophore model of cyclic tetrapeptides described above. In MOR, Trp318(7.35) forms an aromatic interaction with Phe3 of JOM6, supporting the important role of Trp318(7.35) in peptide binding to MOR. 56 Similarly, in KOR Tyr312(7.35) forms an aromatic interaction with Phe3 of MP16. The smaller size of the binding pocket in KOR relative to that in MOR, owing to extra residues inserted into EL2, prevents the binding of tetrapeptides with bulkier side chain substitutions in the Phe3 position. Indeed, the Trp3 analog of MP16, which cannot be accommodated between Phe214(EL2), Leu309(E3), and Tyr312(7.35) without some side chain and backbone shift, demonstrates decreased affi nity. 26 On the other hand, the open space in MOR between the corresponding Phe221(EL2), Thr315(EL3), and Trp318(7.35) is large enough to accommodate the 1-Nal3-containing analog of JOM6, which shows high binding affi nity. 148 The m -, d -, and k -selectivity of opioid cyclic tetrapeptides is also largely affected by their C-terminal groups. The C-terminal -COO -of JOM13 forms favorable ionic interaction with N ε + of Lys214(5.39) inside the DOR binding pocket, thus explaining the preference of a C-terminal free carboxylate for d -selectivity. In the receptor-bound conformations of JOM6 and MP16, their carboxamide groups are spatially shifted closer to Glu210(5.35) of MOR or to Glu297(6.58) of KOR. Therefore, in order to avoid electrostatic repulsion between negatively charged groups, a neutral C-terminus is required for high affi nity of m -and k -peptides.
The calculated agonist-bound and inactive state models of MOR, DOR, and KOR 26 , 34 , 70 were used for subsequent docking of nonpeptide agonists and antagonists, respectively. The ligands were positioned to provide the best overlap of the message tyramine (or tyramine-like) moieties and to satisfy known SAR and key receptor-ligand interactions, starting with the largest rigid ligands. Ligands from each structural class were analyzed separately. To account for the intrinsic fl exibility of the receptor an ensemble of 5 to 10 models, calculated with a distinct set of spatial constraints, was used for ligand docking.
All opioid ligands interact with the same binding pocket; however, smaller ligands only partially occupy the available space, leaving some empty areas, which could be fi lled by several fl exible " rotating " side chains from TMs and loops. The key rotating residues in the binding pocket include Asp(3.32), Met(3.36), Trp(6.48), Lys/Trp/Glu(6.58), and Trp/Leu/Tyr(7.35), with most of these being implicated in receptor activation. 56 , 64 , 65 Similar to the cyclic tetrapeptides, nonpeptide agonists form an H-bond and ionic interaction between their amine N + and the trans rotamer of Asp(3.32), and a " stacking " interaction between aromatic tyramine ring and the indole ring of Trp(6.48), which can be slightly adjusted ( c 2~0 ± 20°) to better accommodate different ligands ( Figure 4 ) . Unlike peptide ligands, the tyramine hydroxyl of nonpeptide agonists only interacts as an H-donor with backbone -C=O of Ala(5.46) but cannot interact with His(6.52). The 
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functionally important a -hydroxyl or carbonyl at C-6 of opiates can form an H-bond with Lys(5.39) and Tyr(3.33), while a hydroxyl group at C-14 can form an H-bond with Tyr (3.33) . The large aromatic moiety of d -selective nonpeptide agonists (SIOM, TAN67) interacts with the indole ring of Trp284(6.58) of DOR, which is consistent with the important role of Trp284(6.58) in binding of these ligands, as suggested from DOR mutagenesis. 37 , 59 , 60 Morphine and its small analogs can be positioned similarly to the larger opiates. However, in the large MOR binding pocket they can also occupy certain alternative positions. In particular, these different positions can allow the irreversible morphine analogs, MET-CAMO, 149 BAM, or S-activated dihydromorphine derivatives 150 to form a covalent bond with Cys321(7.38). The fentanyl analog, cis-2S,3R,4S-ohmefentanyl, can be positioned in the MOR binding pocket in an extended conformation, 18 with its phenethyl group imitating the tyramine part of opiates and peptides, and its 4-phenylpropanamide, forming aromatic interactions with Trp318(7.35), similar to Phe3 of peptides. Positioned this way, the fentanyl analog ' s N + can form an ionic interaction with Asp147(3.32) and an H-bond with Tyr148(3.33), while its 2 ' OH can form an H-bond with Tyr148(3.33). A similar arrangement of this fentanyl analog in MOR has been proposed 57 based on mutagenesis data. 57 , 58 The comparison of the agonist-bound MOR 70 with our previously calculated inactive MOR 34 reveals that the major changes in the binding pocket are related to the side chain rotation of Trp293(6.48) from a rotamer with c 1~-60°, c 2~90° to a rotamer with c 1~-60° and c 2~0° ( Figure 5 ). As a result, the indole ring of Trp293 (6.48) relocates from the interface between TMs 6 to 7 to the interface between TMs 3 to 5 -6, where it can form a " stacking " interaction with the aromatic ring of Tyr1 of JOM6. Inactive and agonist-bound bound states of receptor also differ in the relative position of 2 key residues, Asp(3.32) and His(6.52), the suggested partners for the tyramine moiety of opioid ligands. In the inactive state Asp(3.32) assumes a gauche + rotamer ( c 1~-60°), which, instead of forming an H-bond/ionic interaction with the protonated amine of the The comparison of agonist and antagonist positioning in the agonist-bound and the antagonist-bound KOR conformations is demonstrated in Figure 5 . Because of the differences in the interaction of the ligands with the key residues Asp138(3.32), Trp287(6.48), His291(6.52), and Tyr312(7.35), the antagonist norBNI is placed with its amine N + shifted more deeply into the pocket relative to MP16. The antagonist activity of morphine analogs is usually associated with an N-allyl or N-cyclopropylmethyl substituent on this amine N + , while an N-methyl substituent is associated with agonists. 154 Because of added steric bulk and the deeper positioning in the pocket, the N-cyclopropylmethyl group of norBNI locks Asp138(3.32) and indole ring of Trp287(6.48) in the " inactive " orientations. Moreover, the central part of the " address " moiety of norBNI, which overlaps with the cyclic ring of tetrapeptides, forms favorable hydrophobic interactions with the trans (ie, inactive) rotamer of Tyr312(7.35), while its N-17 ' basic nitrogen forms an ionic interaction with Glu297(6.58), consistent with experimental observations. 61 Such models of agonist and antagonist interactions with ORs can explain the observed larger effect of His(6.52) mutations and smaller effect of the D147A mutation on the binding of antagonists compared with agonists. 42 , 45 These models also provide a rationale for the recent observations that elimination of the N-terminal amino group converts several peptide agonists to antagonists. 155 The analysis of modes of docking of peptide and nonpeptide agonists and antagonists into ORs using 3-D structures of ligands and receptors provides unique insights into pharmacophore features of agonists and antagonists. The key pharmacophore elements for agonist binding, found from superposition of peptide and nonpeptide agonists inside the receptor binding pocket ( Figures 3 and 4 ) , include (1) positively charged amine ( " N + " ) interacting with Asp(3.32) and, for peptides, with Tyr(3.33); (2) aromatic ring of tyramine ( " A " ) forming " stacking " interactions with Trp(6.48); (3) the central hydrophobic core ( " C " ) interacting with TM6 residues; and (4) the second aromatic ring ( " F " ). The aromatic ring " F " in m -agonists forms essential aromatic interactions with Trp318(7.35). In k -agonists, ring " F " can be smaller, because the corresponding space in KOR near Tyr312(7.35) is smaller and more polar. In d -agonists, ring " F " may be shifted or may extend the central hydrophobic region (to " C1 " ), in order to form aromatic interactions with Trp284(6.58), which serves as the functional counterpart to Trp318(7.35) of MOR. The presence of polar groups (eg, hydroxyl of tyramine, hydroxyl or carbonyl at C-6, C-14 in opiates, 2 ' -OH of ohmefentanyl) can additionally contribute to the binding affi nity of agonists. The key pharmacophore elements for antagonists ( Figures 1 and 5 ) include (1) positively charged ( " N + " ) forming weaker ionic interactions with the more distant Asp(3.32) and amine-aromatic interactions with Tyr(3.33); (2) phenolic ring ( " A " ) forming H-bond with His(6.52); (3) the central hydrophobic core ( " C " ) contacting residues from TM3 and TM6; and (4) additional hydrophobic elements near N + ( " D " ), which can lock Trp(6.48) in the " inactive " orientation. The presence of polar groups (hydroxyl at C-14, positively charged groups for k -ligands) or an aromatic moiety ( " C1 " ) for d -ligands can additionally contribute to antagonist binding affi nity.
In contrast to previously developed ligand-based pharmacophore models of opioid ligands [156] [157] [158] [159] these ligand and receptorderived pharmacophore models not only clarify the available SAR of agonists and antagonists but suggest the role of specifi c ligand groups in the context of receptor structure and provide novel insights into aspects of the receptor environment that have not been previously explored.
CONCLUSIONS
The examples presented above demonstrate that accurate models of MOR, DOR, and KOR can be obtained using homology modeling based on the crystal structure of rhodopsin and distance geometry refi nement with experimentallyderived constraints. Experimental information is required to verify the problematic areas, such as helix distortions and divergent extracellular loops included in the binding pocket. The incorporation of available constraints appropriate for distinct functional receptor states allows modeling of the inactive and agonist-activated receptor conformations separately. Accurate ligand docking guided by experimental ligand-receptor restraints helps explain the known SAR of opioid ligands and the differences between ligand-receptor interactions of peptide and nonpeptide agonists, as well as between agonists and antagonists. The resulting more complete and more contextual ligand and receptor-based pharmacophore models of agonists and antagonists should provide considerable advantages for rational design of compounds directed toward specifi c physiological responses.
